PT - JOURNAL ARTICLE AU - Romanet, Christophe AU - Wormser, Johan AU - Fels, Audrey AU - Lucas, Pauline AU - Prudat, Camille AU - Sacco, Emmanuelle AU - Bruel, Cédric AU - Plantefève, Gaëtan AU - Pene, Frédéric AU - Chatellier, Gilles AU - Philippart, François TI - Effectiveness of endurance training rehabilitation after hospitalisation in intensive care for COVID-19-related acute respiratory distress syndrome on dyspnoea (RECOVER): a randomised controlled, open-label multicentre trial AID - 10.1101/2022.08.29.22279327 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.29.22279327 4099 - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279327.short 4100 - http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279327.full AB - Background COVID-19-related Acute Respiratory Distress Syndrome (CARDS) is the severe evolution of the Sars-Cov-2 infection leading to an intensive care unit (ICU) stay. Its onset is associated with “long-covid” including persisting respiratory disorders up to one year. Rehabilitation is suggested by most guidelines in the treatment of “long-covid”. As no randomised controlled trial did support its use in “long-covid” we aimed to evaluate the effects of endurance training rehabilitation (ETR) on dyspnoea in “long-covid” following CARDS.Methods In this multicentre, two-arm, parallel, open, assessor-blinded, randomised, controlled trial performed in three French ICU, we enrolled adults previously admitted for CARDS, discharged for at least three months and presenting an mMRC dyspnea scale score > 1. Eligible patients were randomly allocated (1:1) to receive either ETR or standard physiotherapy (SP), both for three months. Outcomes assessors were masked to treatment assignment. Primary outcome was dyspnoea’s evolution, measured by Multidimensional Dyspnea Profile (MDP) at inclusion and after 90 days.Results Between August 7, 2020 and January 26, 2022, 871 COVID-19 patients were screened, of whom 60 were randomly assigned to ETR (n=27) or SP (n=33). Mean MDP score after treatment was significantly lower in the ETR group than in the SP group (26.15 [SD 15.48] vs. 44.76 [SD 19.25]; mean difference -18.61 [95% CI -27.78 to -9.44]; p<0.0001).Conclusion CARDS patients suffering from breathlessness three months after discharge improved their dyspnoea significantly more when treated with ETR for three months rather than with SP.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04569266Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethics committee (Comite de Protection des Personnes Sud-Mediterranee III, final approval 29 june 2020, RCB 2020-A01686-33) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors